Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs

Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or refractory to bortezomib and lenalidomide, carries a poor prognosis. The healthcare costs of DRMM have not previously been reported. We analyzed detailed medical resource utilization (MRU) costs, drug costs and out...

Descripción completa

Detalles Bibliográficos
Autores principales: Gooding, Sarah, Lau, I-Jun, Sheikh, Mimi, Roberts, Pamela, Wong, Julia, Dickens, Emmy, Bullement, Ash, Elvidge, Jamie, Lee, Dawn, Ramasamy, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569348/
https://www.ncbi.nlm.nih.gov/pubmed/26367874
http://dx.doi.org/10.1371/journal.pone.0136207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569348/
https://www.ncbi.nlm.nih.gov/pubmed/26367874
http://dx.doi.org/10.1371/journal.pone.0136207

Ejemplares similares